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Trichomonas vaginalis (TV) infection is the most common curable sexually transmitted 
infection (STI).1 In the United States, a population-based survey of females aged 14 to 49 
years in 2001 to 2004 estimated that there were 2.3 million women with prevalent TV 
infections.2 Most infections are asymptomatic.3 In those with symptoms of disease, or 
trichomoniasis, the most common symptoms are vaginitis in women and urethritis in men.3 
T. vaginalis infection is not currently reportable in any US state.
Recently, interest in making TV infection reportable has increased.4 Potential reasons for 
doing so include monitoring epidemiologic trends and stimulating public health research. 
The introduction of highly sensitive and specific nucleic acid amplification tests offers new 
options for making the diagnosis. In addition, researchers have cited associations of TV 
infection with adverse health events such as HIV acquisition, as reasons to make it 
reportable.
In the United States, the Council of State and Territorial Epidemiologists (CSTE) determines 
which conditions should be nationally notifiable by states to the Centers for Disease Control 
and Prevention. However, the authority to require reporting of cases of certain conditions 
resides in the states. Neither CSTE nor individual states have a published set of criteria to 
determine whether a condition should be reportable, although there are public health 
surveillance principles that are used by states and CSTE.
Our objective was to consider systematically whether TV infections should be reportable. 
Specifically, we considered the public health importance of TV infections and, if made 
reportable, whether case reports would be useful and inform public health action.
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To consider whether TV infections should be reportable, we used criteria from the “Updated 
Guidelines for Evaluating Public Health Surveillance Systems,” published in the Morbidity 
and Mortality Weekly Report in 2001, and “Planning a Public Health Surveillance System,” 
published in the Pan American Health Organization Epidemiological Bulletin in 1995.5,6 
These guidelines include lists of criteria for public health importance that a disease or 
condition should meet for surveillance to be recommended.
There are 7 criteria for public health importance described in the guidelines: indices of 
frequency, indices of severity, disparities or inequities associated with the health-related 
event, costs associated with the health-related event, preventability, communicability, and 
public interest.5,6
PUBLIC HEALTH IMPORTANCE OF TV INFECTION
Indices of Frequency
T. vaginalis infection is highly prevalent among sexually active women. A nationally 
representative sample of US females between the ages of 14 and 49 years were tested for TV 
by polymerase chain reaction in the National Health and Nutrition Examination Survey 
(NHANES) in 2001 to 2004. The overall prevalence of TV infection was 3.1%, 
corresponding to an estimated 2.3 million females aged 14 to 49 years infected nationally.2 
In 2005 to 2012, NHANES participants were not tested for TV infection.
Prevalence studies have also been done in select populations. In studies of persons attending 
sexually transmitted disease (STD) clinics, prevalence of TV infection has ranged from 13% 
to 34% in women7 and from 3% to 17% in men.8,9 In studies of incarcerated women, 
prevalence has been as high as 47%.10 T. vaginalis infection is also the most commonly 
diagnosed STI among HIV-infected women receiving care, with reported prevalences of 6% 
to 53%.11–13
Therefore, TV infection clearly meets the frequency criterion.
Indices of Severity
T. vaginalis infection is associated with several adverse health events. In women, TV can 
cause a range of symptoms including mild to severe vaginitis, and symptomatic TV infection 
may increase the risk of adverse pregnancy outcomes including preterm delivery and 
delivery of a low-birth-weight infant.14,15 In men, TV infection can cause nongonococcal 
urethritis, which may result in complications such as prostatitis.16 Multiple observational 
studies suggest that there may be an increased risk of HIV acquisition in women with TV 
infection.17–19 Studies of the impact of TV infection on genital HIV shedding have reported 
mixed results, so it is unclear whether TV in HIV-infected individuals increases the risk of 
HIV transmission to uninfected partners.20–22
However, although symptomatic TV infections are associated with several adverse health 
outcomes, up to 70% of TV infections may be asymptomatic.23 Untreated, the duration of 
infection is unknown but thought to be in the range of a few months to a few years.3,16 
Ultimately, in most infections in men or nonpregnant women at low risk for HIV infection, 
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severe or disabling outcomes are uncommon. Because of this, indices of severity such as 
hospitalization rate, disability rate, and case-fatality rate are likely low for TV infections.
Therefore, it is unclear whether TV infection meets the severity criterion.
Disparities or Inequities Associated With the Health-Related Event
Notable health disparities by race and age have been described for TV infections. Among 
women tested for TV in NHANES in 2001 to 2004, the prevalence of TV infection among 
non-Hispanic black women was 10 times the prevalence among non-Hispanic white women 
(13.1% compared with 1.3%).2 T. vaginalis prevalence also varied by age in the NHANES 
data, increasing from 2.1% in women aged 14 to 19 years to 4.0% in women aged 30–39 
years.2
Therefore, TV infection clearly meets the associated disparities criterion.
Costs Associated With the Health-Related Event
Estimating the direct and indirect medical costs due to TV infection is difficult because so 
many infections are asymptomatic and because recent national data on incidence and 
prevalence are limited. In a study of insurance claims for trichomoniasis among women with 
employer-sponsored private insurance in 2001 to 2005, the average direct medical cost per 
episode was $101.24 This study estimated that the annual economic burden of trichomoniasis 
nationally was $6.8 million among women with private insurance and $18.9 million among 
all women in the United States. Assuming that the costs of asymptomatic TV infection are 
negligible, these are relatively low costs compared with those of other common STIs such as 
chlamydia or herpes simplex virus 2, both of which have annual direct costs of more than 
$500 million in the United States.25 However, the estimated direct medical costs of TV 
infections do not include costs of sequelae associated with infection, such as HIV infection 
or preterm birth, or indirect costs such as time lost at work. The cost of implementing case 
reporting and control for TV infections, though, could easily exceed the estimated direct 
medical costs.
Therefore, it is unclear whether TV infection meets the costs criterion for public health 
importance.
Preventability
Primary prevention of TV infection may be possible on an individual level through 
consistent and correct use of latex condoms.26 Currently, there is no control program for TV 
infection beyond clinical management of individuals diagnosed as having TV infection and 
treatment of their sexual partners. In most cases, TV infection is easily treated with a single 
dose of metronidazole or tinidazole.27
On a population level, a reduction in prevalence would likely require widespread screening 
in combination with timely treatment of patients and their partners, which would be costly 
and burdensome for STD programs due to the high prevalence of infection. Furthermore, it 
is unclear whether a control program would be successful in reducing the prevalence of TV 
infection. Chlamydia, another curable STI that is usually asymptomatic, has been reportable 
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in all 50 states since 2000, with national screening recommendations targeting adolescent 
and young adult women.27 Even so, bringing screening recommendations to scale and 
ensuring partner treatment for chlamydia are ongoing challenges. The continued high 
prevalence of chlamydia among young women despite reporting and screening efforts 
suggests that prospects for reducing the prevalence of TV infection through these 
approaches would be challenging, as well.
Therefore, it is unclear whether TV infection meets the preventability criterion for public 
health importance.
Communicability
T. vaginalis infection has a high transmission rate to sexual partners. Among women with 
TV infection, 14% to 60% of their male sexual partners are also infected, and among men 
with TV infection, 67% to 100% of their female partners are also infected.16,28 Data on 
transmissibility of TV infection between sex partners of the same sex are limited.
Therefore, TV infection meets the communicability criterion.
Public Interest
Public interest regarding TV infection is low. In a 1996 survey of Americans aged 18 to 64 
years, only 2% were able to name trichomoniasis (or “trich”) when asked to list STDs.29 
There are no current data on TV knowledge and awareness, but it is not expected to be 
considerably higher because there have been no major media or social marketing campaigns 
for TV like those for chlamydia or other STIs. Making TV infection reportable could 
increase public interest, but at a large financial cost to the public health and medical care 
systems.
T. vaginalis infection does not meet the public interest criterion.
In summary, at this time, TV infection clearly meets only 3 of 7 criteria for a condition of 
public health importance that warrants recommended surveillance (Table 1).
CASE REPORT DATA
Finally, it is important to consider exactly what would be measured by potential case reports 
of TV infection. The Centers for Disease Control and Prevention recommends that HIV-
infected women should be screened annually for TV infection, but screening 
recommendations are lacking for other asymptomatic individuals.27 Owing to this lack of 
national screening recommendations and because most cases of TV infection are 
asymptomatic, data from case reports would measure diagnostic testing trends, rather than 
true incidence. Thus, case reports would underestimate the true burden of infection. 
Therefore, case report data are not expected to be useful in monitoring trends in TV 
infection or targeting prevention and control efforts.
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CONCLUSIONS AND FUTURE DIRECTIONS
T. vaginalis infection should not be reportable at this time. T. vaginalis infection clearly 
meets only 3 of 7 criteria for conditions of public health importance that warrant 
surveillance (frequency, associated disparities, and communicability). Furthermore, it is 
unclear whether effective public health interventions could be implemented if TV infections 
were made reportable. Even if made reportable, potential case report data would be difficult 
to interpret because case reports would not represent the true incidence of TV infection.
Effective surveillance systems exist apart from case reporting, and the burden of TV 
infection can be monitored through a less costly, yet valid system. Prevalence estimates from 
national population-based surveys such as NHANES can provide estimates of disease 
prevalence that are not biased by screening coverage. In addition, sentinel surveillance can 
provide useful information on emerging issues, such as recent data from the STD 
Surveillance Network on TV antimicrobial drug resistance.30 Cross-sectional surveys of 
select populations, particularly those at high risk for HIV infection, may be another more 
cost-effective surveillance system for monitoring local trends in TV infection.
Further studies are needed to develop the evidence base for TV infection to be considered an 
STI of higher public health priority. These should include studies of (1) the current 
epidemiology of TV infection and symptomatic trichomoniasis, (2) the true burden of 
disease and public health impact of infection (e.g., nucleic acid amplification test tests could 
be used to confirm or refute results from earlier studies suggesting an association between 
TV infection and preterm birth or other adverse outcomes), and (3) treatment options and 
alternatives in case of nitroimidazole allergy or antimicrobial drug-resistant trichomoniasis. 
In addition, studies of the effectiveness of public health interventions conducted at the 
population level are needed to inform future TV control efforts.
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TABLE 1
Public Health Importance Criteria5,6
Characteristic Description Does TV Infection 
Meet the Criterion?
Indices of frequency What are the incidence and prevalence? Yes
Indices of severity What is the case-fatality ratio, hospitalization rate, or disability rate? Unclear
Disparities or inequities associated with 
the health-related event
Does prevalence vary across populations? Yes
Costs associated with the health-related 
event
What is the socioeconomic burden of the event? Unclear
Preventability Can public health interventions prevent or control the disease? Unclear
Communicability What is the infectiousness of incident cases? Yes
Public interest What is the current level of concern in the population about the 
disease?
No
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